3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT1B/1D ligands

被引：2

作者：

Egle, I ^{[1
]}

MacLean, N ^{[1
]}

Demchyshyn, L ^{[1
]}

Edwards, L ^{[1
]}

Slassi, A ^{[1
]}

Tehim, A ^{[1
]}

机构：

[1] NPS Pharmaceut Inc, Mississauga, ON L4V 1V7, Canada

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 03期

关键词：

D O I：

10.1016/j.bmcl.2003.11.023

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of 3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives (2) has been prepared using parallel synthesis techniques, and their structure-activity relationships studied. High affinity human 5-HT1B/1D (h5-HT1B/1D) ligands have been identified. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：727 / 729

页数：3

相关论文

共 16 条

[1] Constitutive activity at serotonin 5-HT1D receptors:: detection by homologous GTPγS versus [35S]-GTPγS binding isotherms [J].

Audinot, V ;

Newman-Tancredi, A ;

Millan, MJ .

NEUROPHARMACOLOGY, 2001, 40 (01) :57-64

[2] Advances in pharmacological treatment of migraine [J].

Diener, HC ;

Limmroth, V .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (10) :1831-1845

[3] (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity h5-HT1B/1D ligands [J].

Egle, I ;

MacLean, N ;

Demchyshyn, L ;

Edwards, L ;

Slassi, A ;

Tehim, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (20) :3419-3421

[4] THE DEVELOPMENT OF A HIGHLY SELECTIVE 5-HT(1) RECEPTOR AGONIST, SUMATRIPTAN, FOR THE TREATMENT OF MIGRAINE [J].

FENIUK, W ;

HUMPHREY, PPA .

DRUG DEVELOPMENT RESEARCH, 1992, 26 (03) :235-240

[5] 5-HT1 RECEPTORS IN MIGRAINE PATHOPHYSIOLOGY AND TREATMENT [J].

FERRARI, MD ;

SAXENA, PR .

EUROPEAN JOURNAL OF NEUROLOGY, 1995, 2 (01) :5-21

[6]

*GLAX WELLC INC, 2001, PHYS DESK REF, P1399

[7] THE MODE OF ACTION OF SUMATRIPTAN IS VASCULAR - A DEBATE [J].

HUMPHREY, PPA ;

GOADSBY, PJ .

CEPHALALGIA, 1994, 14 (06) :401-410

[8]

Isaac M, 2001, IDrugs, V4, P189

[9]

KAMBOJ R, 1999, IBC 3 ANN C MIGR NOV

[10] Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system:: Implications for the discovery of new antimigraine drugs [J].

Longmore, J ;

Shaw, D ;

Smith, D ;

Hopkins, R ;

McAllister, G ;

Pickard, JD ;

Sirinathsinghji, DJS ;

Butler, AJ ;

Hill, RG .

CEPHALALGIA, 1997, 17 (08) :833-842